Real-world multicentre experience of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer
Background : Afatinib is an irreversible, second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that has been shown to be more potent than platinum doublet chemotherapy as well as the firstgeneration EGFR-TKI in patients with EGFR-mutant advanced non-small cell lu...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Conference or Workshop Item |
Language: | English English |
Published: |
2019
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/86231/1/WCLC2019%20poster_Real%20World%20Multicenter%20Experience%20of%20First-line%20Afatinib_25Aug2019.pdf http://irep.iium.edu.my/86231/7/WCLC2019-Abstract-Book_web-friendly.pdf http://irep.iium.edu.my/86231/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|